Narcolepsy is a disabling neurlogical illness

that usually begins early in life. It manifests as sleep

disturbances and REM sleep phenomena that intrude
into the lives of affected individuals. There are two
subtypes of the disorder: narcolepsy with cataplexy and
narcolepsy without cataplexy. The cause is uncertain,
but there is evidence of both genetic and environmental
factors. The brain peptide hypocretin appears to be
defcient in most cases involving cataplexy. There are
several co-morbid conditions linked to narcolepsy,
especially other sleep disorders. The symptoms overlap
with many medical and psychiatric illnesses, which can
result in misdiagnosis. Therefore, careful history along
with objective sleep data gathered in polysomnography
and multiple sleep latency testing are needed to make an
accurate diagnosis. Stimulant medications, modafnil,
Narcolepsy: Clinical features, co-morbidities & treatment
Jeremy Peacock & Ruth M. Benca
Department of Psychiatry, University of Wisconsin-Madison, USA
Received November 24, 2008
Narcolepsy is a neurologic illness that typically begins in the second and third decades of life. It is chronic
in nature and negatively impacts the quality of life of affected patients. The classic presentation is a tetrad
of excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations. The exact
cause remains unknown, but there is signifcant evidence that hypocretin defciency plays an integral
role. Some primary conditions that result in secondary narcolepsy include traumatic brain injury,
congenital disorders, tumours, and strokes. Some medical and psychiatric disorders share characteristics
of narcolepsy, at times leading to diagnostic inaccuracy. Other sleep disorders are commonly co-morbid.
Diagnosis relies on patient history and objective data gathered from polysomnography and multiple sleep
latency testing. Treatment focuses on symptom relief through medication, education, and behavioural
modifcation. Both classic pharmacological treatments as well as newer options have signifcant problems,
especially because of side effects and abuse potential. Novel modalities are being examined to expand
options for treatment.
Key words Cataplexy - excessive daytime sleepiness - hypocretin - MSLT - narcolepsy
and sodium oxybate target the excessive daytime
sleepiness while antidepressants and sodium oxybate
are useful for cataplexy. Therapies that focus on
various neurotransmitter systems, immunomodulation,
and hypocretin replacement are being evaluated.
Epidemiology
The prevalence of narcolepsy varies across
countries and with different ethnic groups, and so the
exact prevalence is not known. Discrepancies may
relate in part to disease defnitions, study designs, and
age groups studied. Prevalence estimates have been
reported to be between 168 and 799 per 100,000 in
most studies, although Japanese studies have indicated
a higher prevalence of 1600 per 100,000
1,2
. None of
these studies used polysomnography in their diagnostic
338
Indian J Med Res 131, February 2010, pp 338-349
Review Article
approach, however, and instead relied on survey data.
An estimated incidence of 0.74 per 100,000 person-
years for a diagnosis of narcolepsy with cataplexy and
1.37 per 100,000 person-years for patients diagnosed
narcolepsy with and without cataplexy was based
on the incidence rates and prevalence of narcolepsy
in Olmsted County, Minnesota between 1960 and
1989, as measured by the record linkage system of
the Rochester Epidemiology Project
3
.

The prevalence
of narcolepsy without cataplexy is more diffcult
to ascertain, and these patients are more likely to be
undiagnosed; this subgroup may represent 10 to 50 per
cent of the narcolepsy population
4,5
.
Narcolepsy can begin at any age, although the
majority of the people diagnosed with narcolepsy begin
to show symptoms between the ages of 10 and 25 yr
6
.
There may be a bimodal distribution with a signifcant
but smaller peak occurring in the fourth decade of life
7
.
Younger populations report that excessive daytime
sleepiness (EDS) is the frst symptom to appear,
whereas older cohorts report that cataplexy is the
most common initial symptom
6
.

Men seem to be more
commonly affected, with narcolepsy occurring 1.6
times more often in men than in women
1
.
Although the specifc causes of narcolepsy remain
unknown, it appears that there are both environmental
and genetic factors contributing to the development
of this disease. Supporting the evidence for an
environmental infuence is the fact that the disease is
not apparent at birth, but instead commonly has its
onset during the second decade of life. Additionally,
there are apparent precipitating factors such as head
trauma, infection, and changes in sleep-waking habits
that have been identifed in some cases
8
.

A higher
incidence of narcolepsy has been seen in people born in
the month of March and a lower incidence among those
born in September
9
.

While most cases of narcolepsy
are sporadic, there are multiple reports of familial
narcolepsy
10
. First-degree relatives have an estimated
a 1 to 2 per cent chance of developing narcolepsy
10
.
Although small, it is substantially higher than the
prevelance of narcolepsy in the general population.
Narcolepsy is associated with the HLA DR2
haplotype
11
. Because of this observation, it has
been postulated that narcolepsy may result from an
autoimmune process, though this has not been verifed
11
.
DNA analysis has revealed that there are several
genes linked to narcolepsy. Moreover, different gene
subtypes carry various levels of frequency, specifcity,
and relationship to ethnic backgrounds
10
. However,
these genes can also be found in subjects who do not
appear to have symptoms of narcolepsy. There has
been a strong association observed with HLA DQB1
0602/DRB1 1501, which is particularly prevalent when
cataplexy is present
11
; over 90 per cent of narcoleptics
with cataplexy express this marker, but it is also seen
in approximately 1/10 1/3 of the general population.
Confounding this is the fact that there are rare patients
with obvious cataplexy who do not have HLA DQ B1
0602, thus HLA typing is not useful as a diagnostic
tool
10
.

Role of hypocretin
Hypocretin is a peptide derived from the
dorsolateral hypothalamus that has been linked to
multiple regulatory functions including sleep/wake
cycles, food intake, and pleasure seeking behaviour
12
.

Sleep fragmentation is observed when there is a
defciency of hypocretin. There are currently two
known variants, hypocretin 1 and 2, also known as
orexin A and B, respectively. Hypocretin functions
through two G protein coupled receptors. The cells
containing hypocretin are linked to monoamine
cell groups in the locus ceruleus, raphe nucleus,
tuberomammillary nucleus, and ventral tegmental
area corresponding to norepinephrine, serotonin,
histamine, and dopamine respectively. Defciencies
of hypocretin can lead to abnormailities in the
function of these monoamine systems, which in turn
can mediate the symptoms of narcolespy. Dopamine
has signifcant wakefulness promoting properties, as
does histamine. Abnormalities related to rapid eye
movement (REM) sleep can be produced with the
changes to the adrenergic and serotonergic systems
13
.
Animal studies provided some of the earliest
evidence that hypocretin plays some role in narcolepsy
14
.
Certain breeds of dogs, including Doberman Pinschers,
can express the narcoleptic phenotype that is transmitted
by an autosomal recessive gene. Study of these animals
has revealed the presence of fragmented sleep, episodes
thought to be similar to cataplexy, and short REM
sleep latencies. Genetic analysis led to the discovery
of a dysfunctional receptor in the neuropeptide system,
specifcally hypocretin 2 receptor. Studies in mice
revealed a model in which mutations found in the
preprohypocretin promoter produce the narcolepsy
phenotype
14
. Hypocretin 2 receptor knockout mice
also display episodes similar to cataplexy
15
. Animals
without the hypocretin 1 receptor are not observed
to have cataplexy-like behaviours, but do show
fragmentation of their sleep.
PEACOCK & BENCA: NARCOLEPSY- DIAGNOSIS & TREATMENT 339
With animal studies yielding evidence of a
link between narcolepsy and abnormalities in the
hypocretin system, attention has turned to hypocretin
in human narcolepsy
16
. Human pathology studies have
revealed reductions of Hcrt1, Hcrt2, and preproHcrt
mRNA. However, only one report so far has found
mutations in the Hcrt gene itself
16
. The resultant
low level of hypocretin despite normal Hcrt genes
lends some weight to the idea that narcolepsy is the
result of an autoimmune process. Also in support of
this idea is that narcolepsy has a typical onset in the
second and third decades of life, which is common
in many other autoimmune disorders. One report has
identifed monozygotic twins who were concordant for
narcolepsy with cataplexy but found to have normal
cerebral spinal fuid concentrations of hypocretin-1
and no mutations in the hypocretin gene or hypocretin
receptor gene, suggesting that dysfunction of the
hypocretin system may not be the only pathway to
narcolepsy
17
.

In human narcolepsy, the role of hypocretin system
abnormality appears to be variable
16
. Many studies
have found hypocretin to be absent or reduced in the
cerebrospinal fuid of narcoleptics; over 90 per cent
of patients show signifcant reductions in hypocretin
levels when there is clear cataplexy and HLA
positivity
12,18
. However, this association is not as clear
when cataplexy is absent, with only approximately 20-
40 per cent of non-cataplectic patients showing low
hypocretin levels. The lack of low CSF hypocretin may
represent an entirely different entity with pathology in
another system versus a less severe form of the disease.
Additionally, this may represent secondary narcolepsy
resulting due to from tumours, traumatic brain injury,
and encephalomyelitis
19
. Alterations in hypocretin
have not been seen in other sleep disorders such as
sleep apnoea, insomnia, and restless leg syndrome
11
.
On the other hand, there are many other disorders with
symptoms of daytime sleepiness or fatigue that have
been associated with low CSF hypocretin levels such
as encephalitis, multiple sclerosis, genetic disorders,
tumours, and Guillian-Barre syndrome
12
.

Clinical features
The classic tetrad of symptoms for narcolepsy
includes excessive daytime sleepiness (EDS), cataplexy,
sleep paralysis, and hypnagogic hallucinations
8
. Not all
symptoms are present in all patients and these may vary
and in frequency and intensity over time
6,20
. Also, these
symptoms can be found in other disorders, including
other distinct sleep disorders
21
.

Excessive daytime sleepiness includes spontaneous,
recurring urges to sleep and a general sense of
background sleepiness that is present much of the time;
this is the most commonly occurring feature of the
tetrad
22
. These episodes vary in length from seconds to
over an hour. Patients with narcolepsy may experience
multiple episodes of overwhelming sleepiness per day.
The sleep attacks can occur at inappropriate times
such as driving, when engaged in conversation, and
other times the patient is active and participating in
some task. This urge to sleep tends to be heightened
by more monotonous activity or in low stimulation
surroundings. Narcoleptics often report that taking a
nap or succumbing to these sleep attacks help them,
as they often feel refreshed upon waking, although
usually only for a short period. Patients with narcolepsy
generally do not spend a greater portion of their time
asleep compared to people who do not have narcolepsy
despite these recurring daytime sleep spells because
their nocturnal sleep is often highly fragmented; this
results in a loss of total sleep time at night so that the
added daytime napping results in a normal amount
of total sleep across the day
23
. The background level of
sleepiness can also have signifcant impact on daytime
functioning, impairing concentration, work and school
performance, and general quality of life
24,25
.
It is important to clarify that the narcoleptic patient
is sleepy and not just fatigued, although both symptoms
are often reported. Clinicians and patients often use
these terms interchangeably, although these do not
necessarily describe the same entity. Fatigue refers to
lacking energy or feeling listless, as opposed to having
a true tendency to fall asleep inappropriately. Fatigue is
associated with many medical and psychiatric illnesses.
Individuals who suffer from fatigue do not usually
exhibit abnormal results on multiple sleep latency
testing
24
.

Cataplexy is a sudden decrease in or loss of muscle
tone. It usually occurs bilaterally and is often in
response to emotions such as humour, anger, surprise,
and tremendous joy
22,23
. These attacks typically affect
certain muscle groups but may be more generalized,
resulting in the patient collapsing. Patients with
narcolepsy are often aware of these attacks and take
action such as propping themselves up or sitting down
when as they perceive the attack coming on. There may
be twitching of the facial muscles or limbs which can
lead to a misdiagnosis of epilepsy
22
. In milder versions,
patients may describe a general sense of weakness but
still maintain control. Speech may be slurred or broken
340 INDIAN J MED RES, FEBRUARY 2010
as a result of muscle inhibition. Patients may also
complain of simply feeling clumsy or unco-ordinated,
particularly at times involving strong emotions. It is
possible for cataplexy to emerge without the event
being triggered by an emotion or stress, but this is
more unusual. Typically, cataleptic episodes are
brief, lasting a few seconds to a few minutes. In rare
circumstances, these can persist for hours, resulting in
status cataplecticus.
In normal sleep, NREM sleep always occurs frst
and then alternates with REM sleep. Because of the
early onset REM periods and dissociation of certain
components of REM sleep, a patient may experience
other aspects of REM sleep during wakefulness
20,22,23
.
In normal REM sleep, the body loses muscle tone, and
dreaming occurs. Sleep paralysis occurs as a patient
with narcolepsy is either falling asleep or awakening.
This can be a frightening experience because the patient
is unable to move limbs, open the eyes, or speak. These
episodes are generally brief and patients are aware of
their state. Often, hallucinations coincide with sleep
paralysis.
Patients with narcolepsy may experience
hallucinations at sleep onset (hypnagogic) and upon
awakening (hypnopompic)
20,22,23
. Like normal dreams,
these phenomena tend to be visual in nature but may
also be auditory. Characteristically, these include
simple forms, objects, animals, and people. Patients will
sometimes respond to their hallucinations, particularly
if they believe that an intruder is present or that they
are in some form of danger. Patients also report other
types of dream-like phenomena which might include
levitation or out of body experiences.
In addition to the classic tetrad, patients also
describe signifcant problems with insomnia, repeated
awakenings, and complaints related to their level of
tiredness such as blurry vision, diploplia, and trouble
with concentration and memory
22,23,26
. There are often
automatic behaviours that occur at the time of increasing
sleepiness
22
. These automatic behaviours are generally
related to routine activities that require little attention
but may involve signifcant errors or risk, such as
driving. Narcolepsy is often co-morbid with other sleep
disorders such as REM sleep behaviour disorder, sleep
apnoea, and periodic limb movement disorder
24,27
.
The symptoms of narcolepsy and secondary effects
of the disorder can have major negative effects on all
aspects of life including the patient's education, work
performance, ability to drive safely, relationships,
mood, and overall wellbeing.
Of the four symptoms in the classic tetrad, excessive
daytime sleepiness is the one most consistently reported
by patients with narcolepsy
28
. Evaluating this complaint
is problematic, however, because it is observed in
numerous other disorders related to sleep and many
general medical and psychiatric disorders. Several
primary sleep disorders have daytime sleepiness as a
symptom, including sleep deprivation, delayed sleep
phase disorder, advanced sleep phase disorder, sleep
disordered breathing, periodic limb movements,
idiopathic hypersomnia, and Kleine-Levin syndrome.
Excessive daytime sleepiness is routinely linked
to psychiatric disorders as well
24,28
. Epidemiologic
studies have revealed signifcant co-morbidity of
hypersomnia and psychiatric disorders. Dysthymia,
atypical depression, seasonal affective disorder, and
bipolar disorder are commonly associated with sleep
dysregulation and complaints of hypersomnia. Several
anxiety disorders may also impact the patient's sleep
and should be evaluated and addressed
29,30
.
Causes of narcolepsy
The exact cause of primary human narcolepsy
remains unknown, although loss of hypocretin appears
to play a role in most cases with cataplexy
12,18
. There
are also other neurological insults that appear to have
narcolepsy symptoms as a consequence
19
. Just as in
primary narcolepsy, these entities may or may not
include cataplexy as a symptom. Measurement of
CSF hypocretin levels may reveal a broad range of
variations in the low, normal, and intermediate range
as well
8
. Lesions of the hypothalamus and nearby
structures can produce narcolepsy-like symptoms.
Multiple sclerosis, tumours, and strokes have all been
associated with narcolepsy as well. More global insults
such as traumatic brain injury, encephalomyelitis,
and congenital disorders such as Neimann-Pick type
C disease, myotonic dystrophy, and Prader-Willi
syndrome are also associated with narcolepsy
8
. It
is unknown if the changes in hypocretin levels are a
consequence of the primary insult or a coincidental
fnding. Additionally, these changes can be transient,
as the low levels found in many traumatic brain injury
patients may return to normal after six months
12
.

Diagnostic considerations
The International Classifcation of Sleep Disorders
consists of two classifcations of narcolepsy: with or
without cataplexy
21
. The tetrad of EDS, cataplexy,
sleep paralysis, and hallucinations is the hallmark of
narcolepsy, though not all of the symptoms need be
PEACOCK & BENCA: NARCOLEPSY- DIAGNOSIS & TREATMENT 341
present (Table I). Also, some of the symptoms may be
present in isolation even if a patient has experienced
the whole tetrad. For example, cataplexy may be
seen without necessarily having a sleep attack, and
sleep attacks do not necessarily include an episode of
cataplexy. Because excessive daytime sleepiness is
the most common feature in patients with narcolepsy,
having methods to determine levels of sleepiness
accurately is important. Several scales exist to measure
sleepiness, including the Epworth Sleepiness Scale
31
.
A common problem with subjective scales, however, is
their inconsistent reliability to correlate with objective
data.
The multiple sleep latency test (MSLT) is currently
the accepted standard to obtain objective information
regarding sleep drive and excessive sleepiness. It
consists of fve scheduled naps, each 20 min in length,
that are scheduled every 2 h across the day. Ideally, the
sleeping conditions are set so that the patients are best
able to fall asleep. This requires appropriate temperature,
limited stimulation, and making the nap as comfortable
as possible given the obvious limitations of being in
the lab and attached to recording equipment. Following
each nap opportunity, the patient is to stay awake until
the next scheduled nap. During the test, physiologic
data are gathered such as the time it takes to fall asleep
and the presence or absence of REM sleep. REM sleep
that occurs within the frst 15 min of sleep, an event
termed sleep onset REM (SOREM), rarely occurs
in normal individuals, but is common in narcolepsy.
MSLT results may vary with the age of the patient
32
.
The current criteria require falling asleep in less than
eight minutes on average across the naps and having
two SOREMs or the occurance of REM sleep within
the 20 min naps
21
. There is some evidence that this
criteria are not specifc to narcolepsy. Having multiple
SOREMs on the MSLT has been associated with other
disorders with EDS such as sleep apnoea, shift work
sleep disorder, and periodic limb movement disorder
33
.
Kleine-Levin syndrome, Prader-Willi, obsessive-
compulsive disorder, and Parkinson's disease have also
been linked to SOREMs
33
. Multiple SOREMs have
rarely been seen in patients who were thought to be
otherwise normal.
On the night prior to an MSLT, the patient is
typically brought into the sleep laboratory in order to
perform the nocturnal polysomnogram. The patient
is monitored all night to gather data on breathing,
movement, time in bed, time asleep, and heart rate. The
patient also will have electroencephalogram (EEG)
recorded throughout the night to monitor when the
patient falls asleep and wakes up, as well as to provide
information regarding what stages of sleep are attained
and the length of those stages. While the EEG montage
is limited, it has the potential to identify seizure activity.
Patients may have audio and video monitoring to
reveal snoring, sleep talking, and reveal movements or
complex behaviours that the patient may be performing
while asleep. The polysomnogram itself may reveal the
aetiology of a person's excessive daytime sleepiness or
other sleep pathologies. Narcolepsy can be co-morbid
with other sleep disorders such as REM behaviour
disorder, apnoea, and sleep related movement
disorders. Conversely, the sleep study procedure may
cause a person to have abnormal sleep because of the
disruption of sleeping in a new environment and with
the recording electrodes, thus potentially infuencing
the next day's MSLT, particularly if the patient had
signifcant diffculty falling asleep or staying asleep in
the laboratory. To minimize the effects of possible sleep
deprivation, the American Academy of Sleep Medicine
recommends that the patient have at least six hours
of recorded sleep on the night prior to the MSLT
34
.
This could still be insuffcient for a given individual,
however, and ideally a patient should sleep ad libitum
for at least several days prior to being studied in the
laboratory.
At its most basic level, an MSLT measures
sleepiness. It does not determine what causes the
observed sleepiness. Because of this, a condition that
would promote one's ability to take multiple naps
during the daytime could signifcantly interfere with
the validity of using MSLT to diagnose narcolepsy.
Further complicating the issue is that many of the
symptoms of narcolepsy, with the exception of
cataplexy, can be produced with suffcient sleep
deprivation
35,36
. Co-morbid medical and psychiatric
conditions could contribute to an increased tendency
to fall asleep during the day. Numerous medications
Table I . Primary and secondary aetiologies
Hypocretin defciency
Hypothalamic lesion
Stroke
Tumour
Prader-Willi syndrome
Traumatic brain injury
NeimannPick disease type C
Myotonic dystrophy
Encephalomyelitis
342 INDIAN J MED RES, FEBRUARY 2010
can also interfere with the validity of the test. As data
are gathered regarding REM sleep, medications that
either suppress or promote REM sleep can affect test
results. As such, medications that can alter alertness,
sleep cycle, and other physiologic data that would
be recorded during the test should be reduced or
eliminated for at least several weeks prior to the test,
if possible.
A signifcant confounder for the MSLT is insuffcient
sleep time since many people are chronically sleep
deprived
35
. Therefore, a complaint of EDS requires
taking detailed history and gathering data on a person's
sleep
35
. To further assist in making the diagnosis,
patients may be asked to keep a sleep diary in order
to verify their sleep habits, time in bed, and attempt to
learn how much time is spent sleeping each day. There
is some evidence that such logs may be unreliable in
comparison to actigraphy, which consists of wearing
a motion sensitive device that records when there is
motion and uses the lack of movement as a surrogate
for time asleep.
There are no genetic tests currently available for
clinical use to make a positive diagnosis of narcolepsy.
Genetic testing may correlate best to narcolepsy
when there is already clear cataplexy
8,12
. Additionally,
the genes identifed so far are specifc to various
ethnic backgrounds, further limiting their utility
10,37
.
There are also no blood tests available to confrm a
diagnosis. Analysis of CSF is useful in patients who
also have typical cataplexy. Atypical cataplexy, which
involves a cataplectic event that is not initiated by an
emotional event such as laughter, is only associated
with hypocretin defciency in 20 per cent of cases
8
.
In evaluating patients for narcolepsy with cataplexy,
almost all cases with defcient hypocretin are also
positive for HLA DQB1
8,11,18
. It is important to keep in
mind that narcolepsy does not exclude other diagnoses
from being co-morbid, and conversely, narcolepsy
symptoms may be secondary to some other conditions
such as traumatic brain injury, infection, tumour, or
cerebrovascular accident
8
.

Multiple sclerosis (MS) is
particularly problematic because the common HLA
DQB1 haplotype can be seen in MS, and plaques in
the hypothalamus could potentially lead to secondary
narcolepsy. It is reasonable to expect these chance
plaques to be the cause of sleep related symptoms,
because MS patients positive for HLA DQB1, but
lacking plaques in the hypothalamus, do not show
changes in hypocretin and do not exhibit the tetrad of
narcolepsy symptoms.
Differential diagnosis
Narcolepsy shares many symptoms with psychiatric
illnesses, which can sometimes lead to it being
diagnosed as a psychiatric illness. According to the
Fourth edition of the Diagnostic and Statistic Manual
IV with text revision (DSM-IV-TR), nearly every
psychiatric illness requires some level of functional
impairment
30
. Patients with narcolepsy can exhibit
signifcant problems in work, school, relationships,
and their quality of life, and these types of impairments
may bring them to psychiatric attention
19,25
. Common
psychiatric illnesses such as major depressive disorder
(MDD), bipolar disorder, and psychotic disorders have
symptom overlap with narcolepsy
23
. Patients with mood
disorders often have insomnia and/or hypersomnia
38
.
Patients with MDD or who are in the depressed phase of
bipolar disorder may experience EDS in addition to their
fatigue
39
. Mood disorder patients in general can show
polysomnographic fndings of reduced REM latency
when not taking REM suppressing antidepressants
38
.
However, these generally do not result in SOREM
periods as seen in narcolepsy. Mood disorders can
be associated with psychosis, and hypnagogic/
hypnopompic hallucinations may be interpreted as
psychotic symptoms
40
. Patients with psychiatric illness
and those with narcolepsy can express some level of
impairment in cognitive performance
30,41
. In children,
narcolepsy may present with just EDS
42
. Consequently,
the behaviours observed as a result of the sleepiness
may mimic that seen in children with attention defcit/
hyperactivity disorder
43
. To further confound the
diagnosis, both often respond to treatment with stimulant
medications and there is evidence of improvement in
paediatric patients with attention defcit hyperactivity
disorder (ADHD) who take modafnil
44
. Malingering is
another possibility, as patients may be seeking medical
leave, disability, or seeking stimulants. Narcolepsy can
also be misdiagnosed as a conversion disorder.
Schizophrenia and narcolepsy also share some
features that can lead to misdiagnosis and thus
inappropriate treatments
24
. Both tend to start in
adolescence and young adulthood. Patients with
schizophrenia can have alterations in the sleep cycle and
complain of insomnia. Some schizophrenics may have
reduced REM sleep latencies. Hallucinations are found
in both, though a careful history and detailed assessment
of these can help distinguish the two entities. Auditory
hallucinations are experienced by both groups, though
much more commonly in patients with schizophrenia.
Conversely, visual hallucinations are reported by
PEACOCK & BENCA: NARCOLEPSY- DIAGNOSIS & TREATMENT 343
patients with narcolepsy in rates as high as 83 per cent
while seen by patients with schizophrenia only 29 per
cent of the time
40
. Further, patients with narcolepsy
usually report their hallucinations to be associated with
sleep and those with schizophrenia do not generally
link these phenomenon to their sleep. As opposed to
the case of narcolepsy misdiagnosed as ADHD, the
treatments of schizophrenia and narcolepsy do not often
overlap. In fact, providing stimulants to a patient with
schizophrenia may worsen their psychotic symptoms.
Conversely, many antipsychotic medications may
worsen EDS because of their sedative side effects.
Depending on the neurotransmitters affected by a given
agent, there can be myriad effects on sleep architecture
that may be inadvertently benefcial. For example,
REM sleep suppression may help with cataplexy and
the hypnagogic hallucinations. Thus, the clinician
and patient may be led astray by the resolution of the
psychotic symptoms.
Several neurologic disorders should be considered
when making the diagnosis of narcolepsy. Epilepsy is
a commonly occurring condition that may be given as
the initial diagnosis
45
. The cataplexy and sleep attacks
may appear to an observer to be a seizure. Parkinson's
disease and Alzheimer's disease both exhibit signifcant
alterations in sleep and prominent EDS
46,47
. There is
also an overlap in Parkinson's disease and narcolepsy
because of their shared association with REM sleep
behaviour disorder
46
. The presence of hallucinations
may confuse patients and clinicians. Treatment
strategies for these neurologic disorders may overlap,
particularly with dopamine agonist medications,
though such agents can also cause sleep attacks and
worsen symptoms of Parkinson's disease.
Treatment of Narcolepsy
As a defnitive cause of narcolepsy has yet to be
identifed, treatment strategies must focus on relief of
symptoms. With EDS being the most prevalent and the
most problematic issue for narcoleptics, most of the
treatments target this particular symptom
8
.

Stimulant
medications have been the mainstay of therapy for
many decades
4,13
. These medications primarily act by
increasing monoaminergic activity. Those medications
that infuence dopamine and norepinephrine have been
the most effective for managing EDS, but do not typically
provide refief from cataplexy, though some patients
do fnd that amphetamines can reduce this symptom as
well. Thus amphetamines and methylphenidate, in their
various formulations, have been the most commonly
utilized pharmacotherapy. Both of these mediations
are available in immediate release and longer acting
formulations. Adderall is given in doses of 10-60 mg
per day, with 60 mg being the maximum total daily
dose. Methylphenidate comes in numerous brands and
dosage formulations. The usual dosages are between
10 and 60 mg per day, though this will depend on the
actual brand and formulation chosen
4,13
.
These medications can have profound side effects,
and can be addictive
48,49
. Because of the noradrenergic
effects, amphetamines can cause hypertension. Patients
with high blood pressure, cardiac disease, symptomatic
hyperthyroidism, and arteriosclerosis should use
amphetamines with caution
49
. Both methylphenidate
and amphetamines have been linked to signifcant
substance abuse, in part thought to be mediated by their
role with increasing dopamine levels. In some patients,
stimulants can also produce or exacerbate co-morbid
psychiatric complications such as anxiety, mania, and
even psychosis. Because narcoleptic patients often
have insomnia, the time of day when stimulants are
taken must be monitored, so as not to produce even
more sleep disturbance. Loss of appetite, sometimes
with weight loss, and motor tics are associated with
stimulants.
Modafnil is approved by the United States
Food and Drug Administration for the treatment of
excessive sleepiness related to narcolepsy, obstructive
sleep apnoea/hypopnoea syndrome, and shift work
sleep disorder
50
. Its mechanism of action is not fully
understood, but it is believed to work through the
dopaminergic, adrenergic, and histaminergic systems
in the hypothalamus
13,51
. This difference led to it being
termed a wakefulness promoting agent rather than a
stimulant. While it appears useful for the treatment
of EDS, it also seems to be benefcial for cataplexy
13
.
The therapeutic range is 100 to 400 mg each day
50
.
Dosing it multiple times per day can reduce residual
EDS compared to a single daily dose
52
. One drawback,
though, is compliance with the second daily dose,
which may then hinder the true effectiveness of
this medication. The most common side effects are
headache, dry mouth, insomnia, nausea, and anxiety
50,52
.
Some people also experience cardiovascular effects
including tachycardia, palpitations, or chest pain.
There can be serious dermatologic reactions and
hypersensitivity including Stevens-Johnson syndrome
and toxic epidermal necrolysis. Neurocognitive
complaints include diffculty in concentrating,
depression, and paresthesias. While no causative link
344 INDIAN J MED RES, FEBRUARY 2010
has been established, the literature reveals case reports
of patients taking modafnil and experiencing suicidal
ideation
50,53
. There are also reports linking modafnil
to visual hallucinations in mania
50
. Modafnil is
currently not scheduled as other stimulant medications.
Compared to other medications useful for EDS, it does
not appear to have the same level of abuse potential.
Multiple studies have been conducted in which
modafnil is compared to traditional stimulant
medication, with mixed results
4
. In studies involving
a placebo, modafnil and stimulants were both superior
in terms of reducing EDS. However, subjects already
familiar with the effectiveness of amphetamines at times
requested to be switched back to these medications,
as they did not believe they were adequately treated
with modafnil alone because of a subjective sense of
sleepiness
4
. Additionally, some reported that they did
not have a strong sense of control over their cataplexy
and sleep paralysis. As amphetamines interact with the
norepinephrine system they may show some additional
benefts for these symptoms. Studies that revealed no
particular difference between stimulants and modafnil
generally used longer washout periods, and subjects
received modafnil at its upper dosage limits
4
. With
treatment, subjects reported improvements in quality
of life, mood, and a higher level of satisfaction with
modafnil compared to stimulants
54
(Table II).

Modafnil is not currently approved for treatment
in children. However, it is prescribed to children and
appears to be effective
55
. In a small study of modafnil
in children ages 2-18 yr, it was associated with
improvements in academic performance and further
showed improvement in objective measures on MSLT
55
.
There is some evidence that it is most effective when
used in divided doses, with one in the morning and
another in the afternoon
43
. Care should be taken not to
administer modafnil in such a way that would impair
the child's sleep.
Another medication found to be effective for
the treatment of cateplexy and EDS is gamma-
hydroxybutyric acid (GHB). It is produced for
sale in the US as sodium oxybate, the salt form of
GHB
43
. Historically, GHB has been utilized for many
different conditions such as depression, insomnia, and
alcoholism
56
. In the United States, it is currently only
approved to treat cataplexy and EDS associated with
narcolepsy and is the only medication approved by the
US FDA for cataplexy
57
. The properties of GHB can
appear to be paradoxical
56
. Because of its interaction
with the GABA system, which is inhibitory, it can act
as a sedative. However, in relative low doses it can
stimulate dopamine release, and at higher doses inhibit
dopamine release, thereby resulting in both inhibitory
and stimulating central nervous system effects. It also
appears to promote glutamate release, further enhancing
its stimulating properties.
The effectiveness of sodium oxybate has been
established in placebo controlled trials
4
. There are also
studies in which subjects have taken sodium oxabate
after being on other available treatments for EDS
58
.
In this comparative study of modafnil versus sodium
oxybate, both objective and subjective measures were
assessed, utilizing the maintenance of wakefulness
test and Epworth sleepiness scale, respectively.
Findings from the study revealed that both subjective
and objective effects of sodium oxalate were superior
compared to treatment with modafnil
58
. The same
study also found that modafnil did not separate from
placebo, however.
GHB has been associated with signifcant abuse,
dependence, and withdrawal
59
. Street users have called
it liquid ecstasy, as it can produce euphoria and has
been utilized in the nightclub scene
56
. It has also been
called a date rape drug, being associated with sexual
assault. It has been utilized by bodybuilders because
of its ability to stimulate human growth hormone. It
is contraindicated for use with other CNS depressants,
and has synergistic effects with alcohol
57
. Abrupt
discontinuation of GHB can result in life-threatening
withdrawal
60
. Because of its shared agonism with
Table II. Treatment - behavioural and pharmacological (for
excessive sleepiness and cataplexy)
Behavioural
Ensure good sleep hygiene (avoid sleep deprivation)
Consider use of strategic napping
Pharmacological: For excessive sleepiness
Methylphenidate
Amphetamine
Modafnil
Selegiline (also anti-cataplectic)
Pharmacological: For cataplexy
Gamma-hydroxybutyric acid/sodium oxybate
Protriptyline
Desipramine
Imipramine
Clomipramine
Venlafaxine
Duloxetine
Selective serotonin reuptake inhibitors
PEACOCK & BENCA: NARCOLEPSY- DIAGNOSIS & TREATMENT 345
GABA, baclofen is very useful in the treatment of
GHB withdrawal
61
. Overdoses of GHB can result
in signifcant CNS sedation, respiratory depression,
bradycardia, and seizures
57
.
As sodium oxybate, it can have important
cardiovascular effects secondary to water balance in the
face of heightened sodium levels
57
. At the maximum
recommended human dose of 9 g, it contains 1638 mg
of sodium. As such, patients who have heart failure,
hypertension, or renal impairment may need additional
evaluation prior to starting sodium oxybate. It undergoes
signifcant frst pass metabolism in the liver, so patients
with hepatic impairment should be started at one-half
the usual dosage.
Common side effects of sodium oxybate include
headache, nausea, dizziness, nasopharyngitis,
somnolence, vomiting, and urinary incontinence
20,57
.
There are also reports of obstructive sleep
apnoea worsening while taking sodium oxybate.
Somnambulism, or sleep walking, occurred in 4 per
cent of the subjects in the clinical trials submitted for
FDA approval
57
. However, in patients who had been
exposed to the drug for up to 16 yr, the incidence of
sleep walking increased to 32 per cent
57
. Because of
the dangers inherent in somnambulism, patients must
be cautioned regarding this potentially problematic
effect.
Selegiline is another agent used to reduce EDS
4
.
Selegiline is an irreversible monoamine oxidase
inhibitor (MAOI) with selectivity for MAO-B
13
.
As the dose increases, it can lose the selectivity and
block both the A and B subtypes. It has wakefulness-
promoting properties and can also reduce cataplexy, in
part thought to be a result of its REM sleep suppressing
properties. Selegiline has signifcant disadvantages
though, as it requires a low tyramine diet and has
numerous interactions with other medications. Patients
should be counselled regarding the numerous foods
and medications that are restricted with ongoing MAOI
use. Many medications, including antidepressants
which may have been used to control cataplexy, need a
washout period prior to initiating an MAOI.
While modafnil and stimulants are the mainstay
of treatment for EDS, these are not often effective
for cataplexy
13
. In contrast, sodium oxybate improves
nocturnal sleep, relieves EDS, and has anticataplectic
properties as well. Aside from sodium oxybate,
antidepressants (TCAs) used for decades. The exact
mechanism for this effect is not fully known, but
it is thought that the suppression of REM sleep is
responsible. Other REM related symptoms (sleep
paralysis and hypnagogic hallucinations) are
improved with TCA usage. Routinely used TCAs
include protriptyline, desipramine, and imipramine.
Clomipramine causes the maximum serotonergic
blockade, often resulting in substantial REM
suppression. The signifcant side effects of TCAs such
as their cardiovascular effects, especially conduction
changes, may limit their use. Anticholinergic effects
such as blurred vision, urinary retention, orthostatic
hypotension, constipation, dry mouth, and dizziness are
common as well. Sexual side effects occur frequently.
In addition to the side effects, TCAs have important
withdrawal complication, particularly for narcoleptics,
in that patients may experience rebound cataplexy. In
rare circumstances, the cataplexy may progress to status
cataplecticus, impairing function for hours or days.
With the effectiveness of TCAs in treating
cataplexy, it follows that other antidepressants may
prove useful as well
13
. Selective serotonin reuptake
inhibitors (SSRIs) have been shown to reduce
cataplexy, but the literature base is limited. Like TCAs,
these can suppress REM sleep. Other antidepressants
are also reported to have effectiveness. Venlafaxine and
duloxetine, both serotonin- norepinephrine reuptake
inhibitors, have been used successfully
62
. However,
venlafaxine usage is linked to tolerance and return of
the symptoms
47
. In a small sample, duloxetine was
not found to produce tolerance at one year of follow
up
62
. The advantage that newer antidepressants hold
over older TCAs is in their lesser side effects. Given
the usual age of onset of narcolepsy, it is important to
consider the potential moods changes in adolescents
and young adults and the FDA warnings associated
with antidepressant usage in this population
63
. Sexual
side effects, headaches, gastrointestinal changes, and
sleep changes are common with these medications.
Venlafaxine is associated with sustained hypertension.
Also, there are numerous possible drug-drug interactions
with many of the antidepressants, particularly the older
TCAs and MAOIs.
Given the possible immune mediated nature
of narcolepsy, plasmapheresis and intravenous
immunoglobulin are interesting potential options. In a
small series, cataplexy was reduced using intravenous
immunoglobulins (IVIG)
64
. In follow up, however,
there was still a need for treatment of EDS
65
. Canine
narcolepsy has responded to immunosuppresive agents
such as steroids, azothiaprine, and methotrexate when
346 INDIAN J MED RES, FEBRUARY 2010
administered shortly after birth and the dogs raised in
a controlled environment
66
. It appeared effective for
cataplexy and consolidated sleep. A few human cases
have been reported in which steroids have been used
to treat for other conditions and then patients noticed
that their narcolepsy symptoms also diminished
67,68
.
Tiprolisant is an inverse histamine H(3)-receptor agonist
that has been used in a small study of 22 subjects
68
.
It appears to have wakefulness promoting properties,
affecting the noradrenergic and histaminergic systems.
Subjective sleepiness was reduced on the Epworth
Sleepiness Scale (ESS) by nearly six points compared
to one point with placebo. Hypocretin replacement
therapies are also being explored
13,20
. Administration
of hypocretin has not been effcacious so far because it
does not cross the blood brain barrier.
In addition to the medication options for treatment,
non-pharmacological approaches are important to
provide optimal care of the patient with narcolepsy.
The powerful sleep drive that results in the sleep
attacks can be temporarily abated by taking naps.
Napping for several minutes to an hour, though, does
not generally suit the demands of most schedules
and can seriously interfere with work or school.
Nonetheless, naps may be necessary for some patients
and arrangements should be made with employers
and schools to accommodate a lunchtime nap and
another in the late afternoon. Good sleep hygiene
is a powerful component of successful treatment,
as sleep consolidation and insomnia are prominent
problems in narcolepsy. Patients should be counselled
regarding the nature of the illness. Given the early
onset and lifelong aspects, career counselling may
be needed as well. Positions that require signifcant
vigilance or concentration for extended periods of
time may be unsuitable options. Shift work jobs and
those with call schedules may also be problematic
for narcoleptics. Driving restrictions are another
important consideration. Because of the rebound
cataplexy with discontinuation of medications,
medication compliance becomes particularly vital
in order to prevent accidents. Worsening EDS is
also implicated in accidents and steps should be
taken to promote wakefulness and reduce driving
while sleepy
69
. In trying to determine what level of
sleepiness is too sleepy to drive, multiple approaches
have been taken, with conficting results. In one large
study, ESS predicted an increased risk of accidents
when controlling for driver demographics, driving
distance, weekly alcohol use, and the per cent of
nighttime driving
69
. In another study, however, ESS
and neuropsychiatric evaluation did not predict
accidents when compared to driving simulations
70
.
Summary
Narcolepsy is classically a tetrad of symptoms
including EDS, cataplexy, sleep paralysis, and
hypnagogic hallucinations. The exact pathophysiology
is not yet known, but hypocretin defciency appears to
play a signifcant role, especially in cases with cataplexy.
Narcolepsy is associated with several other sleep
disorders as well as a variety of medical and psychiatric
illnesses. The symptoms of narcolepsy can overlap with
many other disorders, at times leading to misdiagnosis
and inappropriate treatments. Diagnosis is made by
taking a careful history along with polysomnography
followed by an MSLT. While not defnitive, having two
periods of SOREM sleep is usually accepted as objective
evidence to make the diagnosis. Stimulants have been
the primary treatment of EDS and antidepressants are
useful in the REM related aspects such as cataplexy.
Attention to sleep hygiene and strategic use of daytime
naps may also be helpful. Newer pharmacologic options
are available that may have improved side effect profles
and/or greater effcacy in comparison to older treatments.
Novel approaches are being explored to provide better
resolution of symptoms.
References
1. Longstreth WT, Jr., Koepsell TD, Ton TG, Hendrickson AF,
van Belle G. The epidemiology of narcolepsy. Sleep 2007; 30 :
13-26.
2. Tashiro T, Kanbayashi T, Iijima S, Hishakawa Y. An
epidemiological study on prevalence of narcolepsy in
Japanese. J Sleep Res 1992; (Suppl 1) : 228.
3. Silber MH, Krahn LE, Olson EJ, Pankratz VS. The
epidemiology of narcolepsy in Olmsted County, Minnesota: a
population-based study. Sleep 2002; 25 : 197-202.
4. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF.
Treatment of narcolepsy and other hypersomnias of central
origin. Sleep 2007; 30 : 1712-27.
5. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault
C. HLA DQB1*0602 is associated with cataplexy in 509
narcoleptic patients. Sleep 1997; 20 : 1012-20.
6. Ohayon MM, Ferini-Strambi L, Plazzi G, Smirne S, Castronovo
V. How age infuences the expression of narcolepsy. J
Psychosom Res 2005; 59 : 399-405.
7. Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze
B, Besset A, et al. Age at onset of narcolepsy in two large
populations of patients in France and Quebec. Neurology
2001; 57 : 2029-33.
8. Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment
in sleep and neurological disorders. Lancet Neurol 2008; 7 :
649-62.
PEACOCK & BENCA: NARCOLEPSY- DIAGNOSIS & TREATMENT 347
9. Picchioni D, Mignot EJ, Harsh JR. The month-of-birth pattern
in narcolepsy is moderated by cataplexy severity and may be
independent of HLA-DQB1*0602. Sleep 2004; 27 : 1471-5.
10. Mignot E. Genetic and familial aspects of narcolepsy.
Neurology 1998; 50 (2 Suppl 1) : S16-22.
11. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S,
Overeem S, et al. The role of cerebrospinal fuid hypocretin
measurement in the diagnosis of narcolepsy and other
hypersomnias. Arch Neurol 2002; 59 : 1553-62.
12. Krahn LE, Pankratz VS, Oliver L, Boeve BF, Silber MH.
Hypocretin (orexin) levels in cerebrospinal fuid of patients
with narcolepsy: relationship to cataplexy and HLA
DQB1*0602 status. Sleep 2002; 25 : 733-6.
13. Thorpy M. Therapeutic advances in narcolepsy. Sleep Med
2007; 8 : 427-40.
14. Hungs M, Fan J, Lin L, Lin X, Maki RA, Mignot E.
Identifcation and functional analysis of mutations in the
hypocretin (orexin) genes of narcoleptic canines. Genome Res
2001; 11 : 531-9.
15. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC,
Kisanuki Y, et al. Distinct narcolepsy syndromes in Orexin
Receptor-2 and Orexin null mice molecular genetic dissection
of Non-REM and REM sleep regulatory processes. Neuron
2003; 38 : 715 -30.
16. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay
Y, et al. A mutation in a case of early onset narcolepsy and
a generalized absence of hypocretin peptides in human
narcoleptic brains. Nat Med 2000; 6 : 991-7.
17. Khatami R, Maret S, Werth E, Rtey J, Schmid D, Maly F,
et al. Monozygotic twins concordant for narcolepsy-cataplexy
without any detectable abnormality in the hypocretin (orexin)
pathway. Lancet 2004; 363 : 1199-200.
18. Hong S, Lin L, Jeong J, Shin Y, Han J, Lee J, et al. A study
of the diagnostic utility of HLA typing, CSF Hypocretin-
1 measurements, and MSLT testing for the diagnosis of
narcolepsy in 163 Korean patients with unexplained excessive
daytime sleepiness. Sleep 2006; 29 : 1429-38.
19. Stores G, Montegomery P, Wiggs L. The psychosocial
problems of children with narcolepsy and those with excessive
daytime sleepiness of uncertain origin. Pediatrics 2006; 114 :
198-204.
20. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy.
Lancet 2007; 369 : 499-511.
21. American Academy of Sleep Medicine. International
classifcation of sleep disorders: Diagnostic and coding
manual, 2
nd
ed. Westchester, IL: American Academy of Sleep
Medicine; 2005.
22. Nishino S. Clinical and neurobiological aspects of narcolepsy.
Sleep Med 2007; 8 : 373-99.
23. National Institute of Neurological Disorders and Stroke.
Narcolepsy Fact Sheet. National Institute of Neurological
Disorders and Stroke 2008. Available at: http://www.ninds.
nih.gov/disorders/narcolepsy/detail_narcolepsy.htm, accessed
on August 1, 2008.
24. Benca R. Narcolepsy and excessive daytime sleepiness:
Diagnostic considerations, epidemiology, and comorbidities.
J Clin Psychiatry 2007; 68 (Suppl 13) : 5-8.
25. Ervik S, Abdelnoor M, Heier MS, Ramberg M, Strand G.
Health-related quality of life in narcolepsy. Acta Neurol Scand
2006; 114 : 198-204.
26. Plazzi G, Serra L, Ferri R. Nocturnal aspects of narcolepsy
with cataplexy. Sleep Med Rev 2008; 12 : 109-28.
27. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy
and hypersomnia, and their implications in the hypothalamic
hypocretin/orexin system. Sleep Med Rev 2005; 9 : 269-310.
28. Green PM, Stillman MJ. Narcolepsy. Signs, symptoms,
differential diagnosis, and management. Arch Fam Med 1998;
7 : 472-8.
29. Kluge M, Schssler P, Dresler M, Yassouridis A, Steiger A.
Sleep onset REM periods in obsessive compulsive disorder.
Psychiatry Res 2007; 152 : 29-35.
30. Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision. Arlington, VA: APA; 2000.
31. Johns MW. A new method for measuring daytime sleepiness:
the Epworth sleepiness scale. Sleep 1991; 14 : 540-5.
32. Dauvilliers Y, Gosselin A, Paquet J, Touchon J, Billiard M,
Montplaisir J. Effect of age on MSLT results in patients with
narcolepsy-cataplexy. Neurology 2004; 62 : 46-50.
33. Singh M, Drake C, Roth T. The prevalence of multiple sleep-
onset REM periods in a population-based sample. Sleep 2006;
29 : 890-895.
34. Littner MR, Kushida C, Wise M, Davila D, Morganthaler T,
Lee-Chiong T, et al. Practice parameters for clinical use of
multiple sleep latency test and the maintenance wakefulness
test. Sleep 2005; 28 : 113-21.
35. Black J, Brooks S, Nishino S. Conditions of primary excessive
daytime sleepiness. Neurol Clin 2005; 23 : 1025-44.
36. Leibowitz S, Brooks S, Black J. Excessive daytime sleepiness:
considerations for the psychiatrist. Psychiat Clin N Am 2006;
29 : 921-45.
37. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, et al.
Complex HLA-DR and -DQ interactions confer risk of
narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet
2001; 68 : 686-99.
38. Riemann D. Insomnia and comorbid psychiatric disorders.
Sleep Med 2007; 8 (Suppl 4) : S15 -20.
39. Nofzinger EA, Thase ME, Reynolds CF, Himmelhoch JM,
Mallinger A, Houst P, et al. Hypersomnia in bipolar depression:
a comparison with narcolepsy using the multiple sleep latency
test. Am J Psychiat 1991; 148 : 1177-81.
40. Dahmen N, Kasten M, Mittag K, Mller MJ,. Narcoleptic
and schizophrenic hallucinations. Implications for differential
diagnosis and pathophysiology. Eur J Health Econ. 2002; 3
(Suppl 2) : S94-8.
41. Ha KS, Yoo HK, Lyoo IK, Jeong DU. Computerized
assessment of cognitive impairment in narcoleptic patients.
Acta Neurol Scand 2007; 116 : 312-6.
42. Meltzer LJ, Mindell JA. Sleep and sleep disorders in children
and adolescents. Psychiat Clin N Am 2006; 29 : 1059-76.
43. Peterson PC, Husain AM. Pediatric narcolepsy. Brain Dev
2008; 30 : 609-23.
44. Biederman J, Pliszka SR. Modafnil improves symptoms of
attention-defcit/hyperactivity disorder across subtypes in
children and adolescents. J Pediatr 2008; 152 : 394-9.
348 INDIAN J MED RES, FEBRUARY 2010
45. Macleod S, Ferrie C, Zuberi S. Symptoms of narcolepsy in
children misinterpreted as epilepsy. Epileptic Disord 2005; 7 :
13-7.
46. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep
Med Rev 2005; 9 : 185-200.
47. Lee JH, Bliwise DL, Ansari FP, Goldstein FC, Cellar JS, Lah
JJ, et al. Daytime sleepiness and functional impairment in
Alzheimer disease. Am J Geriatr Psychiatry 2007; 15 : 620-6.
48. Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS,
Slocumb NL. Risks of high-dose stimulants in the treatment of
disorders of excessive somnolence: a case-control study. Sleep
2005; 28 : 667-72.
49. Shire US Inc., "Prescribing Information" sheet (PDF) for
Adderall XR. Available at: http://www.adderallxr.com/,
accessed on August 1, 2008.
50. Cephalon Prescribing Information Sheet (PDF) for Provigil.
Available at: https://www.provigil.com/hcp/default.aspx,
accessed on August 2, 2008.
51. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM,
Yanagisawa M, Miller MS, et al. Hypothalamic arousal
regions are activated during Modafnil-induced wakefulness.
J Neurosci 2000; 20 : 8620-8.
52. Morganthaler TI, Kapur VK, Brown TM, Swick TJ, Alessi
C, Aurora RN, et al. Practice parameters for the treatment
of narcolepsy and other hypersomnias of central origin: An
American Academy of Sleep Medicine Report. Sleep 2006;
29 : 1415-9.
53. Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J,
Solvason HB, Rickels K, et al. Coadministration of modafnil
and a selective serotonin reuptake inhibitor from the initiation
of treatment of major depressive disorder with fatigue and
sleepiness: a double-blind, placebo-controlled study. J Clin
Psychopharmacol 2007; 27 : 614-9.
54. Becker PM, Schwartz JR, Feldman NT, Hughes RJ. Effect
of Modafnil on fatigue, mood, and health-related quality of
life in patients with narcolepsy. Psychopharmacol 2004; 171 :
133-9.
55. Ivanenko A, Tauman R, Gozal D. Modafnil in the treatment
of excessive daytime sleepiness in children. Sleep Med 2003;
4 : 579-82.
56. Tunnicliff G. Sites of action of gamma-hydroxybutyrate
(GHB) - a neuroactive drug with abuse potential. J Toxicol
1997; 35 : 581-91.
57. Jazz Pharmaceuticals. Prescribing Information Sheet (PDF)
for Xyrem. Available at: http://www.xyrem.com/healthcare-
professionals/prescribing-information.php, accessed on
August 1, 2008.
58. Black J, Houghton WC. Sodium oxybate improves excessive
daytime sleepiness in narcolepsy. Sleep 2006; 29 : 939-46.
59. Elliott S, Burgess V. The presence of gamma-hydroxybutyric
acid (GHB) and gamma-butyrolactone (GBL) in alcoholic and
non-alcoholic beverages. Forensic Sci Int 2005; 16 : 289-92.
60. Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from
gamma-hydroxybutyrate, 1,4-butanediol and gamma-
butyrolactone: a case report and systematic review. CJEM
2008; 10 : 69-75.
61. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-
hydroxybutyrate withdrawal. Neurocrit Care 2008; 8 : 430-3.
62. Izzi F, Placidi F, Marciani MG, Zannino S, Torelli F, Corte F, et
al. Effective treatment of narcolepsycataplexy with duloxetine:
A report of three cases. Sleep Med 2009; 10 : 153-4.
63. Wyeth Pharmaceuticals. Prescribing Information Sheet (PDF)
for Effexor XR. Available at: http://www.wyeth.com/content/
showlabeling.asp?id=100, accessed on August 2, 2008.
64. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M.
Successful management of cataplexy with intravenous
immunoglobulins at narcolepsy onset. Ann Neurol 2004; 56 :
905-8.
65. Dauvilliers Y. Follow-up of four narcolepsy patients treated
with intravenous immunoglobulins. Ann Neurol 2006; 60 :
153.
66. Boehmer LN, Wu M-F, John J, Siegel JM. Treatment with
immunosuppressive and anti-infammatory agents delays
onset of canine genetic narcolepsy and reduces symptom
severity. Exp Neurol 2004; 188 : 292-9.
67. Hecht M, Lin L, Kushida CA, Umetsu DT, Taheri S, Einen M,
et al. Report of a case of immunosuppression with prednisone
in an 8-year-old boy with an acute onset of hypocretin-
defciency narcolepsy. Sleep 2003; 26 : 809-10.
68. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier
R, et al. An inverse agonist of the histamine H(3) receptor
improves wakefulness in narcolepsy: studies in orexin-/- mice
and patients. Neurobiol Dis 2008; 30 : 74-83.
69. Powell NB, Schechtman KB, Riley RW, Guilleminault C,
Chieng RP, Weaver EM. Sleepy driver near-misses may
predict accident risks. Sleep 2007; 30 : 331-42.
70. Kotterba S, Mueller N, Leidag M, Widdig W, Rasche K,
Malin JP, et al. Comparison of driving simulator performance
and neuropsychological testing in narcolepsy. Clin Neurol
Neurosurg 2004; 106 : 275-9.
Reprint requests: Dr Jeremy Peacock, Department of Psychiatry, University of Wisconsin-Madison, USA
e-mail: [email protected], [email protected]
PEACOCK & BENCA: NARCOLEPSY- DIAGNOSIS & TREATMENT 349